– ISRAEL, Jerusalem – BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, announced today the appointment of Ms. Ruti Alon to its Board of Directors.
Frank Haluska, M.D, Ph.D., BioCanCell’s President and Chief Executive Officer, commented, “We are extremely pleased to welcome Ruti to BioCanCell’s Board of Directors. Ruti’s background and experience are an excellent fit as we prepare to launch two pivotal clinical trials of our lead investigational agent, BC-819, either of which may lead to registration in early stage bladder cancer. She has a distinguished record of leadership and accomplishment in finance and biotechnology, and she will bring her experience and insight to the strategic guidance of BioCanCell. The Board and the Company very much look forward to her joining us.”
Ms. Alon is currently the founder and CEO of Medstrada. From 1997 to 2016, she served as a General Partner at Pitango Venture Capital, one of the most influential venture firms in Israel. Prior to her tenure at Pitango, Ms. Alon held senior positions with Montgomery Securities from 1981 to 1987, Genesis Securities, LLC from 1993 to 1995, and Kidder Peabody & Co. from 1987 to 1993, and managed her own independent consulting business in San Francisco in the medical devices industry from 1995 to 1996. Ms. Alon was the Founder and Chairperson of Israel Life Science Industry, a not-for-profit organization then representing the mutual goals of approximately 700 Israeli life science companies. She is also the Co-Founder of IATI, Israel Advanced Technology Industries, an umbrella organization to all high-tech and Life Sciences companies in Israel. Ms. Alon has a B.A. in Economics from the Hebrew University of Jerusalem, Israel, and an M.B.A. from Boston University.
Ms. Alon commented, “I am truly excited to have the opportunity to join BioCancell’s Board of Directors. BC-819 has the potential to be the first of its kind DNA-directed cancer therapy. I look forward to being part of BioCanCell as it is targeting this serious unmet medical need.”
Larry Howard, M.D., Chairman of the Board of Directors, added that “Ruti is a successful leader in the Israel biotechnology and life science industry. We will value her perspective and experience as she joins the leadership of BioCanCell.“
Ms. Alon’s appointment has been approved by BioCanCell’s Board of Directors. It will be finalized upon its ratification by a general meeting of shareholders in early September.
BioCanCell is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer. The Company’s most advanced product candidate, BC-819, is in development as a treatment for early stage, non-muscle-invasive bladder cancer (NMIBC). Two registrational clinical trials of BC-819 are planned to be initiated in 2017: a single arm trial in patients whose disease is unresponsive to standard therapy, and a randomized trial, under a special protocol assessment (SPA) from the FDA, in patients who have failed a first course of treatment.
For more information : http://www.biocancell.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.